Table 2 Clinical characteristics of patients with HBV-DNA > 10,000 IU/mL.

From: HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study

Patients’ characteristics

Baseline

Patient

Age/sex

Anti-tumor therapy

Antiviral prophylaxis

HBeAg

AFP (ng/ml)

Child-pugh

BCLC

1

64/M

Combination therapy

ETV

(-)

6.08

A5

B

2

43/M

Lenvatinib

TDF

(+)

3.81

A5

B

3

66/M

Combination therapy

ADV

(-)

132.2

A5

B

4

64/M

Combination therapy

ETV plus TDF

(+)

8.13

B7

C

Patients’ characteristics

At reactivation

Patient

Age/sex

Anti-tumor therapy

Onset (weeks)

HBeAg

HBV DNA

AFP (ng/ml)

Child-pugh

BCLC

Tumor progression

1

64/M

Combination therapy

120

(+)

15,200

5.25

B7

B

Yes

2

43/M

Lenvatinib

16

(+)

23,800

17

B7

B

No

3

66/M

Combination therapy

92

(+)

15,300

3.19

A5

B

Yes

4

64/M

Combination therapy

36

(+)

60,100

5.08

B7

C

Yes

  1. HBeAg, hepatitis B e antigen; AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; M, male; ETV, Entecavir; TDF, Tenofovir; ADV, adefovirdipivoxil.
Back to article page